Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of PD-1 antibody plus genetically modified TIL therapy in gynecological malignancies
ChiCTR2200058937Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Modality
- Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of S(c)TIL and PD-1 Monoclonal Antibody in Cervical Cancer (CC), ovarian cancer and trophoblastic tumour (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Serum beta-human chorionic gonadotropin, Objective response rate and 4 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
S(c)TILPD-1 Monoclonal Antibody
03
Conditions
Cervical Cancer (CC)ovarian cancertrophoblastic tumour
Beyond the preview
Go deeper on ChiCTR2200058937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058937.